We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+38.99%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$51.6M
AUM Growth
-$42.9M
Cap. Flow
-$54.8M
Cap. Flow %
-106.19%
Top 10 Hldgs %
95.77%
Holding
29
New
3
Increased
1
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$1.13M
2
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.05M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$649K
4
FRTX
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
+$174K

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$6.96M
2
AMRN
Amarin Corp
AMRN
+$5.25M
3
AFMD
Affimed
AFMD
+$4.74M
4
STML
Stemline Therapeutics, Inc.
STML
+$4.29M
5
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$3.65M

Sector Composition

Rank Sector Weight
1 Healthcare 96.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-374,431
Closed -$3.47M
STML
27
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-886,632
Closed -$4.29M
IDXG
28
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
– –
-178,295
Closed -$924K
BDSI
29
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-755,000
Closed -$2.86M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Stonepine Capital Management held 29 positions worth $51.6M, down 45% from $94.6M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Stonepine Capital Management withdrew a net $54.8M in Q2 2020, closing 16 positions and reducing 9 holdings. Its most notable exit was Amarin Corp, an estimated $5.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Avalo Therapeutics worth $1.17M.

  • Stonepine Capital Management's largest Q2 2020 buy was Avalo Therapeutics: 156 shares worth $1.17M.
  • Stonepine Capital Management added most to IVERIC bio, Inc. Common Stock in Q2 2020, an estimated $649K increase.
  • Stonepine Capital Management's biggest Q2 2020 reduction was Ligand Pharmaceuticals, cutting an estimated $6.96M.
  • Stonepine Capital Management fully exited Amarin Corp in Q2 2020, selling an estimated $5.25M.
  • Stonepine Capital Management's ten largest holdings make up 96% of its $51.6M portfolio in Q2 2020.
  • Stonepine Capital Management opened 3 new positions and closed 16 in Q2 2020.
  • Stonepine Capital Management's portfolio value fell 45% quarter-over-quarter to $51.6M.

Based on Stonepine Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.